Pharmaceutical-Grade Rigosertib Is a Microtubule-Destabilizing Agent

We recently used CRISPRi/a-based chemical-genetic screens and cell biological, biochemical, and structural assays to determine that rigosertib, an anti-cancer agent in phase III clinical trials, kills cancer cells by destabilizing microtubules. Reddy and co-workers (Baker et al., 2020, this issue of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jost, Marco, Chen, Yuwen, Gilbert, Luke A., Horlbeck, Max A., Krenning, Lenno, Menchon, Grégory, Rai, Ankit, Cho, Min Y., Stern, Jacob J., Prota, Andrea E., Kampmann, Martin, Akhmanova, Anna, Steinmetz, Michel O., Tanenbaum, Marvin E., Weissman, Jonathan S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332992/
https://www.ncbi.nlm.nih.gov/pubmed/32619469
http://dx.doi.org/10.1016/j.molcel.2020.06.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7332992/
https://www.ncbi.nlm.nih.gov/pubmed/32619469
http://dx.doi.org/10.1016/j.molcel.2020.06.008

Ejemplares similares